Suven Life Sciences has secured the processes patents from Europe, Japan and New Zealand. The company has received patents for new chemical entities (NCEs) which are for the treatment of disorders associated with neurodegenerative diseases and these patents are valid through 2034.

Suven Life Science is a biopharmaceutical company focused on discovering, developing and commercialising novel pharmaceutical products, which are best in class CNS therapies using GPCR targets.

These process patents are for company’s pipeline compounds which are in the class of selective 5HT6 compounds and are being developed as therapeutic agents and useful in the treatment of cognitive impairment associated with neurodegenerative disorders like Alzheimer’s disease, Attention deficient hyperactivity disorder (ADHD), Huntington’s disease, Parkinson and Schizophrenia.

Suven Life CEO Venkat Jasti stated that the company is very pleased by the grant of these patents to Suven for the pipeline of molecules in CNS arena that are being developed for cognitive disorders with high unmet medical need with huge market potential globally.